ヤンヘ・ピングチャウンの粒子は,Nrf2アセチレーションを調節することにより,気道滑らかな筋肉細胞の細胞老化を抑制し,気管喘息を改善します
Dezhi Yuan1,2, Xing Yang1,2, Bangfu He1
1The First Affiliated Hospital of Anhui University of Chinese Medicine, NO.117 Meishan Road, Shushan District, Hefei, 230031, Anhui, China.
Respiratory research
|August 31, 2025
まとめ
ヤンヘ・ピンチュアン・グラニュル (YPG) は,SIRT1/Nrf2/HO-1経路を活性化することで,喘息の滑らかな筋肉細胞 (ASMC) の衰老を抑制する. 炎症や酸化ストレスが軽減され 呼吸管喘息の治療に 新しいアプローチが提供されます
科学分野:
- 薬理学について
- 細胞生物学
- 呼吸器医学
背景:
- ブロンキア喘息 (BA) は,広範囲にわたる慢性呼吸器疾患である.
- ヤンヘ・ピンチュアン・グラニュル (YPG) は,伝統的な中国薬で,BA治療に使用されます.
- YPGの正確な治療メカニズム,特に呼吸道滑らかな筋肉細胞 (ASMCs) の細胞老化への影響については,さらなる調査が必要です.
研究 の 目的:
- 呼吸器喘息のラットモデルでのYPGの治療メカニズムを調査する.
- ASMCの細胞老化に対するYPGの影響を in vivoおよびin vitroで調査する.
- YPGの抗喘息効果におけるSIRT1/Nrf2/HO-1信号経路の役割を明らかにする.
主な方法:
- オバルブミン (OVA) を用いてラットに喘息を誘発した.
- ASMCはアルファ・スムーズ筋アクチン (α-SMA) を用いて特定された.
- 試管内および体内実験では,老化マーカー (β-ガラクトシダゼ,P16,P21),酸化ストレス (MDA,SOD,CAT,HO-1),炎症 (IL-1β,IL-4,IL-17),タンパク質発現 (SIRT1,Nrf2) およびタンパク質相互作用 (CO-IP,CO-IF) の測定が行われました.
- SIRT1とNrf2の遺伝子操作 (過剰発現/静止) がASMCで実施された.
主要な成果:
- YPGとSIRT1の過剰発現はASMCの衰老を抑制し,P16,P21,および衰老関連分泌フェノタイプ (SASP) の因子 (IL- 1β,IL- 4,IL- 17) を減少させた.
- YPG治療は,喘息のラットにおける呼吸道組織病理学的損傷を著しく減少させた.
- YPGは,SIRT1,Nrf2,HO-1,SOD,CATの発現を増加させ,MDAのレベルを低下させ,酸化ストレスが減少したことを示した.
- SIRT1はNrf2と相互作用し,Nrf2のアセチル化が低下した.
結論:
- YPGはSIRT1/Nrf2/HO-1信号経路を活性化する.
- この活性化は,SIRT1の発現を調節し,Nrf2アセチル化を調節することによって達成される.
- YPGによるASMC衰老の抑制は,喘息における治療効果に寄与する.
関連する概念動画
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
449
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
449
01:24Antiasthma Drugs: Methylxanthines
395
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
395
01:20Asthma: Pathogenesis and Management
576
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
576
01:19Antiasthma Drugs: Leukotriene Modifiers
461
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
461
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
3.1K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
3.1K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
451
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
451